Cortisol secretion and abnormalities of glucose metabolism in nondiabetic patients with hypertension.

OBJECTIVE Glycometabolic changes are associated with hypercortisolism in Cushing's syndrome. Because impaired glucose tolerance (IGT) and insulin resistance are frequently detected in patients with essential hypertension, we hypothesized that in these patients, early glycometabolic abnormalities might be related to differences in regulation of cortisol secretion. METHODS In a cross-sectional study, we included 155 nondiabetic, essential hypertensive patients who were free of organ complications. The homeostasis model assessment (HOMA) index and the area under the curve of plasma glucose (AUC-glucose) and insulin (AUC-insulin) concentration following an oral glucose tolerance test were measured, together with daily plasma cortisol (8 a.m., 3 p.m. and 12 a.m.; AUC-cortisol) and 8 a.m. cortisol after 1 mg overnight dexamethasone suppression test (DST). RESULTS IGT was present in 27% of patients who were older and had higher BMI, plasma triglycerides and uric acid, AUC-cortisol and DST-cortisol, and lower HDL-cholesterol. Frequency of IGT increased progressively across tertiles of DST-cortisol, together with levels of glycated hemoglobin, fasting insulin and C-peptide, HOMA-index, AUC-glucose, and AUC-insulin. AUC-cortisol and DST-cortisol were directly correlated with insulin, C-peptide, HOMA-index, AUC-glucose, and AUC-insulin. Multivariate regression analysis showed that DST-cortisol was directly and independently correlated with HOMA index, AUC-glucose, and AUC-insulin. In a logistic regression model, both AUC-cortisol and DST-cortisol independently predicted IGT. CONCLUSION Daily cortisol and cortisol response to DST are independent determinants of IGT and insulin resistance in nondiabetic patients with hypertension, suggesting that even subtle differences in regulation of cortisol secretion might increase the risk of these patients to develop diabetes.

[1]  C. Catena,et al.  Association of arterial stiffness with a prothrombotic state in uncomplicated nondiabetic hypertensive patients , 2023, Frontiers in Cardiovascular Medicine.

[2]  Eric L. Johnson,et al.  3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Care in Diabetes-2023. , 2022, Diabetes care.

[3]  Eric L. Johnson,et al.  2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023. , 2022, Diabetes care.

[4]  C. Catena,et al.  Association of non-alcoholic fatty liver disease with left ventricular changes in treatment-naive patients with uncomplicated hypertension , 2022, Frontiers in Cardiovascular Medicine.

[5]  A. Tabarin,et al.  Diagnosis and management of hypertension in patients with Cushing's syndrome: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension , 2022, Journal of hypertension.

[6]  C. Catena,et al.  Differences in Regulation of Cortisol Secretion Contribute to Left Ventricular Abnormalities in Patients With Essential Hypertension , 2022, Hypertension.

[7]  C. Catena,et al.  Vitamin D Deficiency Is Associated with Glycometabolic Changes in Nondiabetic Patients with Arterial Hypertension , 2022, Nutrients.

[8]  C. Catena,et al.  Plasma Lipoprotein(a) Levels as Determinants of Arterial Stiffening in Hypertension , 2021, Biomedicines.

[9]  J. Sowers,et al.  Hypertension in Diabetes: An Update of Basic Mechanisms and Clinical Disease , 2021, Hypertension.

[10]  P. Chanson,et al.  Consensus on diagnosis and management of Cushing's disease: a guideline update. , 2021, The lancet. Diabetes & endocrinology.

[11]  M. Alderman Prediabetes: an unexplored cardiovascular disease risk factor. , 2021, Journal of hypertension.

[12]  Yen-Hung Lin,et al.  Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension. , 2020, Journal of hypertension.

[13]  M. Omura,et al.  Changes in glucose metabolism based on 75-g oral glucose tolerance tests before and after surgery for adrenal Cushing's syndrome. , 2019, Endocrine journal.

[14]  W. Rathmann,et al.  Impaired Glucose Metabolism in Primary Aldosteronism Is Associated With Cortisol Cosecretion. , 2019, The Journal of clinical endocrinology and metabolism.

[15]  Thomas Kahan,et al.  [2018 ESC/ESH Guidelines for the management of arterial hypertension]. , 2019, Kardiologia polska.

[16]  M. Lanaspa,et al.  Fasting blood glucose is predictive of hypertension in a general Japanese population , 2018, Journal of hypertension.

[17]  F. Ceccato,et al.  Diabetes Mellitus Secondary to Cushing’s Disease , 2018, Front. Endocrinol..

[18]  O. Dekkers,et al.  Mortality in patients with Cushing's disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study. , 2016, The lancet. Diabetes & endocrinology.

[19]  M. Kivimäki,et al.  Diurnal Cortisol Patterns, Future Diabetes, and Impaired Glucose Metabolism in the Whitehall II Cohort Study. , 2016, The Journal of clinical endocrinology and metabolism.

[20]  Martin Reincke,et al.  Subclinical hypercortisolism: a state, a syndrome, or a disease? , 2015, European journal of endocrinology.

[21]  C. Catena,et al.  Carotid artery stiffness is related to hyperinsulinemia and insulin-resistance in middle-aged, non-diabetic hypertensive patients. , 2015, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[22]  A. Steptoe,et al.  Association of diurnal patterns in salivary cortisol with type 2 diabetes in the Whitehall II study. , 2014, The Journal of clinical endocrinology and metabolism.

[23]  V. Guarnotta,et al.  Is diabetes in Cushing's syndrome only a consequence of hypercortisolism? , 2014, European journal of endocrinology.

[24]  T. Kuo,et al.  Metabolic functions of glucocorticoid receptor in skeletal muscle , 2013, Molecular and Cellular Endocrinology.

[25]  L. Sechi,et al.  Plasma glucose levels and left ventricular diastolic function in nondiabetic hypertensive patients. , 2013, American journal of hypertension.

[26]  W. Cushman,et al.  Diabetes and hypertension: the bad companions , 2012, The Lancet.

[27]  R. DeFronzo,et al.  Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. , 2011, The American journal of cardiology.

[28]  P. Jones,et al.  Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. , 2011, The Journal of clinical endocrinology and metabolism.

[29]  D. Levy,et al.  Blood Pressure and the Risk of Developing Diabetes in African Americans and Whites , 2011, Diabetes Care.

[30]  P. Nilsson,et al.  Metabolic characteristics of prehypertension: role of classification criteria and gender , 2009, Journal of hypertension.

[31]  J. Holst,et al.  Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes? , 2009, Diabetologia.

[32]  D. Ouwens,et al.  Novel insights into glucocorticoid‐mediated diabetogenic effects: towards expansion of therapeutic options? , 2009, European journal of clinical investigation.

[33]  P. Stewart,et al.  Impaired Glucose Tolerance and Insulin Resistance Are Associated With Increased Adipose 11β-Hydroxysteroid Dehydrogenase Type 1 Expression and Elevated Hepatic 5α-Reductase Activity , 2008, Diabetes.

[34]  A. Stuck,et al.  Age-dependent Decrease in 11 β-Hydroxysteroid Dehydrogenase Type 2 ( 11 β-HSD 2 ) Activity in Hypertensive Patients , 2008 .

[35]  B. Walker,et al.  Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome. , 2008, The Journal of endocrinology.

[36]  R. Krauss,et al.  Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement , 2005, Current opinion in cardiology.

[37]  H. Cohen,et al.  Glucocorticoids Regulate Transcription of the Gene for Phosphoenolpyruvate Carboxykinase in the Liver via an Extended Glucocorticoid Regulatory Unit* , 2005, Journal of Biological Chemistry.

[38]  G. Reboldi,et al.  Adverse Prognostic Significance of New Diabetes in Treated Hypertensive Subjects , 2004, Hypertension.

[39]  L. Sechi,et al.  Serum lipoprotein(a) concentrations and alcohol consumption in hypertension: possible relevance for cardiovascular damage , 2003, Journal of hypertension.

[40]  B. Walker,et al.  Abnormal cortisol metabolism and tissue sensitivity to cortisol in patients with glucose intolerance. , 2002, The Journal of clinical endocrinology and metabolism.

[41]  C. Catena,et al.  Abnormalities of glucose metabolism in patients with early renal failure. , 2002, Diabetes.

[42]  B. Walker,et al.  Elevated plasma cortisol in glucose-intolerant men: differences in responses to glucose and habituation to venepuncture. , 2001, The Journal of clinical endocrinology and metabolism.

[43]  B. Walker,et al.  Glucocorticoids and insulin resistance: old hormones, new targets. , 1999, Clinical science.

[44]  P. Gilon,et al.  Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. , 1997, The Journal of clinical investigation.

[45]  H. Parving,et al.  Prevalence of Arterial Hypertension in Diabetic Patients Before and After the JNC-V , 1994, Diabetes Care.

[46]  S. Agewall Should we do an oral glucose tolerance test in hypertensive men with normal fasting blood-glucose? , 2001, Journal of Human Hypertension.